Clinical utility of the new fluoroquinolones for treating respiratory and urinary tract infections

Expert Opinion on Investigational Drugs

Volumn 10, Issue 2, 2001, Pages 213-237

  Blondeau, J M ^a  

^a ROYAL UNIVERSITY HOSPITAL   (Canada)

Author keywords

Acute pyelonephritis; Antimicrobial resistance; Community respiratory tract infections; Flouroquinolones; Pharmacokinetics; Quinolones; Urinary tract infections

Indexed keywords

ALUMINUM DERIVATIVE; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTACID AGENT; CALCIUM; CEFAZOLIN; CEFEPIME; CEFOXITIN; CEFTAZIDIME; CEFUROXIME; CIPROFLOXACIN; CLARITHROMYCIN; COTRIMOXAZOLE; GATIFLOXACIN; GEMIFLOXACIN; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; MAGNESIUM DERIVATIVE; METICILLIN; MOXIFLOXACIN; NITROFURANTOIN; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TETRACYCLINE; TOBRAMYCIN; TROVAFLOXACIN; UNINDEXED DRUG; VANCOMYCIN;

ANAEROBIC BACTERIUM; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; BIOEQUIVALENCE; CHRONIC BRONCHITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISTRIBUTION VOLUME; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG PENETRATION; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HEADACHE; HUMAN; NAUSEA; PHARMACODYNAMICS; PNEUMONIA; PYELONEPHRITIS; RESPIRATORY TRACT INFECTION; REVIEW; SIDE EFFECT; TASTE DISORDER; URINARY TRACT INFECTION;

ANTI-INFECTIVE AGENTS; DRUG RESISTANCE, MICROBIAL; FLUOROQUINOLONES; HUMANS; RESPIRATORY TRACT INFECTIONS; URINARY TRACT INFECTIONS;

EID: 0035154266     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.10.2.213     Document Type: Review

References (136)

1. Fluoroquinolone antibacterials: SAR, mechanism of action, resistance and clinical aspects
2. Comparative tolerability of the newer fluoroquinolone antibacterials
3. Safety and tolerability of gatifloxacin and advanced-generation 8-methoxy fluoroquinolone
4. A review of clinical trials with fluoroquinolones with an emphasis on new agents
5. The growing problem of nosocomial bacterial resistance. An epidemiological perspective with emphasis on the fluoroquinolones
6. Comparative antimicrobial activity of trovafloxacin tested against 3049 Streptococcus pneumoniae isolates from the 1997-1998 respiratory infection season
7. The Canadian Bacterial Surveillance Network. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada
8. Fluoroquinolone-resistant Moraxella catarrhalis in a patient with pneumonia: Report from the SENTRY Antimicrobial Surveillance Program
9. In vivo selection of Klebsiella pneumoniae strains with enhanced quinolone resistance during fluoroquinolone treatment of urinary tract infections
10. Therapeutic advances of new fluoroquinolones
11. Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin
12. Expanded activity and utility of the new fluoroquinolones: A review
13. Comparative in vitro activity of gatifloxacin, grepafloxacin, levofloxacin, moxifloxacin and trovafloxacin against 4151 Gram-negative and Gram-positive organisms
14. Antibacterial of AM-1155 against penicillin-resistant Streptococcus pneumoniae
15. Antimicrobial activity of gatifloxacin tested against 1,676 Gram-positive cocci resistant to ciprofloxacin: A multicenter organism sample from North and South America
16. Activities of new fluoroquinolones against fluoroquinolone-resistant pathogens of the lower respiratory tract
17. Prognosis and outcomes of patients with community-acquired pneumonia
18. Single- and multiple-dose pharmacokinetics of AM-1155, a new 6-fluoro-8-methoxy quinolone, in humans
19. The new fluoroquinolones: A critical review
20. In vitro and in vivo activity of moxifloxacin against community respiratory tract pathogens
21. Community-acquired pneumonia in adults: Guidelines for management
22. Community-acquired pneumonia
23. A five-year study of severe community-acquired pneumonia with emphasis on prognosis in patients admitted to an intensive care unit
24. Aetiology and treatment of community-acquired pneumonia in adults: An historical perspective
25. Ambulatory patients with community-acquired pneumonia: The frequency of atypical agents and clinical course
26. Acute pneumonia
27. Sequential intravenous/oral ciprofloxacin compared with parenteral ceftriaxone in the treatment of hospitalized patients with community-acquired pneumonia
28. An open-label multicenter noncomparative Phase II/III study of oral gatifloxacin in the treatment of community-acquired bacterial pneumonia (CAP)
29. Treating community-acquired pneumonia with once-daily gatifloxacin vs. once-daily levofloxacin
30. Treating community-acquired pneumonia with once-daily gatifloxacin vs. Twice-daily clarithromycin
31. A randomized, double-blind, multicenter, comparative study of gatifloxacin (GAT) 400 mg IV and PO versus +/- erythromycin (CTX+/-/ERY) in treatment of community-acquired pneumonia (CAP) requiring hospitalization
32. Once-daily 400 mg oral gatifloxacin (GAT) vs. twice daily 500 mg oral clarithromycin (CLA) in the treatment of community-acquired pneumonia (CAP)
33. A randomized, double-blind, multicenter, comparative study of gatifloxacin (GAT) vs. levofloxacin (LEV) in treatment of community-acquired pneumonia (CAP)
34. Levofloxacin and trovafloxacin: The next generation of fluoroquinolones?
35. Levofloxacin. Its use in infections of the respiratory tract, skin, soft tissues and urinary tract
36. Efficacy and safety of moxifloxacin vs. clarithromycin for community-acquired pneumonia
37. Efficacy and safety of moxifloxacin (MFX) vs. clarithromycin (CLR) for the treatment of community-acquired pneumonia (CAP)
38. Moxifloxacin (MXF) versus amoxicillin (AMOX) in the treatment of community-acquired, suspected pneumococcal pneumonia: A multinational, double-blind, randomized study
39. Efficacy and safety of moxifloxacin for the treatment of community-acquired pneumonia
40. Levofloxacin and sparfloxacin: New quinolone antibiotics
41. Randomized, double-blind, comparative study of grepafloxacin and amoxycillin in the treatment of patients with community-acquired pneumonia
42. Trovafloxacin versus high-dose amoxicillin (1 g three times daily) in the treatment of community-acquired bacterial pneumonia
43. Does appropriate antibiotic treatment influence outcome in community-acquired pneumonia (CAP)?
44. Consensus statement: Therapeutic recommendations for community-acquired pneumonia and acute exacerbations of chronic bronchitis
45. Acute exacerbations of chronic bronchitis. An international comparison
46. How do we achieve cost-effective options in lower respiratory tract infection therapy?
47. Managing lower RTIs: A pulmonologist's perspective
48. Chronic bronchitis and acute infectious exacerbations
49. Infective exacerbations of chronic bronchitis. Relation between bacteriologic etiology and lung function
50. Relationship between bacterial flora in sputum and functional impairment in patients with acute exacerbations of COPD
51. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease
52. ATS statement: Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease
53. Recommendations on the management of chronic bronchitis: A practical guide for Canadian physicians
54. A comparison of clarithromycin with ampicillin in the treatment of outpatients with acute bacterial exacerbation of chronic bronchitis
55. Efficacy and safety of once-daily ceftibuten vs. twice-daily ciprofloxacin in the treatment of acute exacerbation of chronic bronchitis
56. Outcome predators in bronchitis
57. Gatifloxacin vs. cefuroxime axetil in patients with acute exacerbations of chronic bronchitis
58. Efficacy and safety of gatifloxacin in the treatment of acute exacerbations of chronic bronchitis
59. Five day moxifloxacin therapy compared with 7 day clarithromycin therapy for the treatment of acute exacerbations of chronic bronchitis
60. Acute community-acquired sinusitis
61. Comparison of moxifloxacin and cefuroxime axetil in the treatment of acute maxillary sinusitis
62. Urinary tract infections in females
63. Evaluation of new anti-infective drugs for the treatment of urinary tract infection
64. Single dose quinolone treatment in acute uncomplicated urinary tract infection in women
65. Short-course ciprofloxacin treatment of acute uncomplicated urinary tract infection in women
66. Single (400 mg) and multiple (200 mg QD) dose oral gatifloxacin (GAT) vs. multiple (100 mg bid) dose oral ciprofloxacin (CIP) in the treatment of acute, uncomplicated urinary tract infection (UTI) in women
67. Urinary tract infections in women: Diagnosis and treatment
68. Urinary tract infection in women. Current role of single-dose therapy
69. Characteristics of pathogens causing urinary tract infections in hospitals: Results from the SENTRY Antimicrobial Surveillance Program, 1997
70. The Canadian National Surveillance Study of urinary tract isolates from outpatients: Comparison of the activities of trimethoprim/sulfamethoxazole, ampicillin, mecillinam, nitrofurantoin and ciprofloxacin
71. Management of bacterial urinary tract infections in adults
72. Levofloxacin versus ciprofloxacin versus lomefloxacin in acute pyelonephritis
73. Rationale for the use of oral fluoroquinolones as empiric treatment of nursing home infections
74. Trends in bacterial resistance to fluoroquinolones
75. A multicenter comparison of gatifloxacin (GAT) 400 mg QD vs. ciprofloxacin (CIP) 500 mg BID in the treatment of complicated urinary tract infection (UTI) and pyelonephritis
76. Comparison of ciprofloxacin (7 days) and trimethoprim/sulfamethoxazole (14 days) for acute uncomplicated pyelonephritis in women
77. Effective short-course therapy of acute exacerbation of chronic bronchitis (AECB) with once-daily gemifloxacin
78. Efficacy of 7 days of gemifloxacin in patients with acute bacterial sinusitis (ABS)
79. Effective once-daily gemifloxacin for the therapy of complicated UTI and pyelonephritis
80. Effective short-course treatment of acute uncomplicated UTI (acute uncomplicated cystitis) with once-daily gemifloxacin
81. The Gemifloxacin 049 Study Group. Efficacy of once-daily gemifloxacin in the treatment of community-acquired pneumonia
82. Safety of gemifloxacin in adult patients with respiratory and urinary tract infections
83. Pharmacokinetics of gemifloxacin administered to patients with severe renal impairment and patients on dialysis
84. Effect of Maalox on the bioavailability of oral gemifloxacin in healthy volunteers
85. QTc prolongation association with levofloxacin
86. The new fluoroquinolones: A critical review
87. In vitro activities of quinolones
88. Therapeutic advances of new fluoroquinolones
89. In vitro activity of gemifloxacin against a broad range of recent clinical isolates from the USA
90. In vitro antibacterial activity of gemifloxacin and comparator compounds against common respiratory pathogens
91. Comparative potency of gemifloxacin, new quinolones, macrolides, tetracycline and clindamycin against Mycoplasma spp
92. Comparative in vitro activity of gemifloxacin
93. Treatment failure and progression of resistance in an outbreak of fluoroquinolones-resistant (FQ) Streptococcus pneumoniae. (Sp.)
94. Effect of fluoroquinolone concentration on selection of resistant mutants of Mycobacterium bovis and Staphylococcus aureus
95. The effect of food on the bioavailability of oral gemifloxacin in healthy volunteers
96. Purification of pneumococcal Type II topoisomerases and inhibition by gemifloxacin and other quinolones
97. SB-265805 (SB) - A potent new quinolone
98. Antimicrobial activity and spectrum of LB20304, a novel fluoronaphthyridone
99. Antipneumococcal activities of gemifloxacin compared to those of nine other agents
100. Comparative in vitro activity of gemifloxacin (SB-265805), a new fluoroquinolone, against respiratory tract pathogens
101. Anti-streptococcal activity of SB-265805 (LB20304), a novel fluoronaphthyridone, compared with five other compounds, including quality control guidelines
102. The in vitro activity and tentative breakpoint of gemifloxacin, a new fluoroquinolone
103. Activities and postantibiotic effects of gemifloxacin compared to those of 11 other agents against Haemophilus influenzae and Moraxella catarrhalis
104. A review of the comparative in-vitro activities of 12 antimicrobial agents, with a focus on five new 'respiratory quinolones'
105. Antibacterial activity of gemifloxacin and 14 comparator compounds against 895 Gram negative clinical isolates
106. In vitro and in vivo evaluations of LB20304, a new fluoronaphyridone
107. In vitro activity of gemifloxacin against Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, Legionella pneumophila and Chlamydia spp
108. Comparative in vitro activity and post-antibiotic effect of gemifloxacin against Legionella spp
109. In vitro activity of gemifloxacin against anaerobes
110. Comparative in vitro antibacterial activity of gemifloxacin against anaerobic bacteria
111. Comparative in vivo activity of gemifloxacin in a rat model of respiratory tract infection
112. Comparative efficacy of gemifloxacin (SB-265805) against experimental respiratory tract infection in rats caused by ciprofloxacin-resistant strains of Streptococcus pneumoniae and Haemophilus influenzae
113. Multiple-dose pharmacokinetics and tolerability of gemifloxacin following oral doses to healthy volunteers
114. Multiple-dose pharmacokinetics and tolerability of gemifloxacin following once-daily repeat oral 320 mg doses to healthy elderly volunteers
115. The pharmacokinetics and tolerability of a single oral dose of gemifloxacin in patients with mild or moderate hepatic impairment
116. In vitro activity and single-dose pharmacokinetics of the (+)- and (-)-enantiomers of gemifloxacin
117. Lack of effect of gemifloxacin on the steady-state pharmacokinetics of theophylline in healthy volunteers
118. Lack of pharmacokinetic interaction between gemifloxacin and digoxin in healthy elderly volunteers
119. Lack of effect of gemifloxacin on the steady-state pharmacodynamics of warfarin in healthy volunteers
120. Effect of omeprazole on the pharmacokinetics of oral gemifloxacin in healthy volunteers
121. Effect of calcium carbonate on the bioavailability of gemifloxacin in healthy volunteers
122. Pharmacodynamics to combat resistance
123. Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men
124. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients
125. Effective short-course therapy of acute exacerbation of chronic bronchitis (AECB) with once-daily gemifloxacin
126. Efficacy of once-daily gemifloxacin (GEMI) for 5 days compared with twice daily clarithromycin (CLARI) for 7 days in the treatment of AECB
127. The efficacy of oral ciprofloxacin vs. clarithromycin for the treatment of acute bacterial exacerbations of chronic bronchitis
128. Gemifloxacin long-term outcomes in bronchitis exacerbations (GLOBE) study - An assessment of health outcome benefits in AECB patients following 5 days gemifloxacin (GEMI) therapy
129. Safety of gemifloxacin in adult patients with respiratory and urinary tract infections
130. Antipneumococcal activity of BAY 12-8039, a new quinolone, compared with activities of three other quinolones and four oral beta lactams
131. Anti-pneumococcal activity of gatifloxacin compared with other quinolone and non-quinolone agents
132. Moxifloxacin: A review of the microbiological, pharmacological, clinical and safety features
133. Mutant prevention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumoniae